• 1
    Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102: 136874.
  • 2
    Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008; 27: 544353.
  • 3
    Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 18398.
  • 4
    Alvarez-Nunez F, Bussaglia E, Mauricio D et al. X. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 2006; 16: 1723.
  • 5
    Mirmohammadsadegh A, Marini A, Nambiar S et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66: 654652.
  • 6
    Khan S, Kumagai T, Vora J et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004; 112: 40710.
  • 7
    Soria JC, Lee HY, Lee JI et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8: 117884.
  • 8
    Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of PTEN/MMAC1/TEP1 gene in human lung cancers. Cancer 1998; 22: 1526.
  • 9
    Forgacs E, Biesterveld EJ, Sekido Y et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998; 17: 155765.
  • 10
    Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 16874.
  • 11
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 41528.
  • 12
    Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004; 4: 111.
  • 13
    Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA hypermethylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002; 21: 545061.
  • 14
    Alberg AJ, Brock MV, Samet JM. Epidermiology of lung cancer: looking to the future. J Clin Oncol 2005; 23: 317585.
  • 15
    Sato K, Tamura G, Tsuchiya T et al. Analysis of genetic and epigenetic alterations of the PTEN gene in gastric cancer. Virvhows Arch 2002; 440: 1605.
  • 16
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 98216.
  • 17
    Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002; 160: 795800.
  • 18
    Marsit CJ, Zheng S, Aldape K et al. PTEN expression in non-small cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathol 2005; 36: 76876.
  • 19
    Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med 2004; 10: 4816.
  • 20
    Marchetti A, Martella C, Felicioni L et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23: 85765.
  • 21
    Toyook S, Maruyama R, Toyook KO et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003; 103: 15360.
  • 22
    Chan EC, Lam SY, Tsang KW et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002; 8: 37416.
  • 23
    Moore LE, Huang WY, Chung J, Hayes RB. Epidermiological considerations to assess altered DNA methylation from environmental exposures in cancer. Ann N Y Acad Sci 2003; 983: 18196.